Intravitreal bevacizumab for the treatment of choroidal haemangiomas

Purpose: To investigate the use of intravitreal bevacizumab for the treatment of subretinal (SRF) and intraretinal fluid associated with circumscribed choroidal haemangiomas (CCH). // Methods: This was a retrospective review of all patients treated with at least 3 bevacizumab injections for CCH-associated SRF between May 2020 and August 2023 in Moorfields eye hospital. Outcome measures included change in best corrected visual acuity (BCVA), change in patient reported symptoms, change in SRF and change in central subfield thickness (CSFT). Data on further management following cessation of injections was analysed. // Results: The study included 9 patients. Median BCVA was 6/19 before and 6/24 after injections (p = 0.41). CSFT decreased from a median of 466 μm to 447 μm (p = 0.11). Two thirds of (n=6) patients did not show any reduction in foveal SRF, one third (n=3) showed a partial reduction and no patients had a complete resolution of SRF. Eight patients received rescue-photodynamic therapy and one received external beam radiotherapy. BCVA changed from a median of 6/60 to a median of 6/12 after rescue treatment (p = 0.63). The median CSFT decreased significantly from 470 μm to 249 μm (p = 0.01). // Conclusions: Intravitreal bevacizumab is unlikely to be an effective treatment for exudative CCH.